Education
About Us
Working with TipRanks
Follow Us
BeOne Medicines Ltd (HK:6160)
:6160
6160 Stock Chart & Stats
HK$182.30
HK$5.50(5.26%)
At close: 4:00 PM EST
HK$182.30
HK$5.50(5.26%)
Day’s Range― - ―
52-Week RangeHK$115.80 - HK$229.40
Previous CloseN/A
Volume1.62M
Average Volume (3M)5.08M
Market Cap
HK$278.64B
Enterprise ValueHK$28.38B
Total Cash (Recent Filing)HK$4.59B
Total Debt (Recent Filing)HK$1.09B
Price to Earnings (P/E)124.8
Beta1.05
Next Earnings
Apr 30, 2026EPS Estimate
0.62Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.36
Shares Outstanding1,540,976,000
10 Day Avg. Volume3,608,600
30 Day Avg. Volume5,076,742
Financial Highlights & Ratios
PEG Ratio-0.80
Price to Book (P/B)7.49
Price to Sales (P/S)6.10
P/FCF Ratio34.63
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$244.26Price Target Upside33.99% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)3.66
Revenue Forecast (FY)HK$50.07B
Bulls Say, Bears Say
Bulls Say
Cash GenerationA material operating cash flow inflection and nearly $0.94B free cash flow in 2025 indicate the business can internally fund R&D, manufacturing scale-up and commercialization. Durable cash conversion supports self-funding of launches and reduces near-term reliance on external financing.
Balance Sheet StrengthA sizable equity base and moderate debt-to-equity give financial flexibility for product launches, regulatory timelines and opportunistic M&A. Manageable leverage lowers refinancing pressure and supports multi-quarter execution on commercialization and late-stage trials.
Clinical/commercial Momentum (ZIIHERA + TEVIMBRA)Phase 3 OS and PFS wins for ZIIHERA with TEVIMBRA represent a structural product opportunity in first-line HER2-positive GEA. Positive pivotal data increases likelihood of label expansion, broad reimbursement and durable revenue streams via a differentiated regimen across geographies and partner channels.
Bears Say
Earnings Durability / Short Profit Track RecordProfitability is nascent after several loss-making years; a single-year inflection reduces confidence in sustained margins. Near-term operational setbacks, slower launches or pricing pressure could reverse gains given limited history of consistent earnings.
Historic Cash Burn And Consistency RiskDespite 2025 cash generation, prior multi-year negative cash flows show execution and financing vulnerability. Renewed investment in launches or trial programs could pressure liquidity if growth stalls, making cash generation consistency a key medium-term risk.
Safety/tolerability Risks For Lead RegimenHigh rates of severe treatment-related adverse events and elevated discontinuations could limit real-world uptake, restrict eligible patient populations, increase monitoring and supportive-care costs, and complicate reimbursement negotiations despite strong efficacy.
BeOne Medicines Ltd News
6160 FAQ
What was BeOne Medicines Ltd’s price range in the past 12 months?
BeOne Medicines Ltd lowest stock price was HK$115.80 and its highest was HK$229.40 in the past 12 months.
What is BeOne Medicines Ltd’s market cap?
BeOne Medicines Ltd’s market cap is HK$278.64B.
When is BeOne Medicines Ltd’s upcoming earnings report date?
BeOne Medicines Ltd’s upcoming earnings report date is Apr 30, 2026 which is in 43 days.
How were BeOne Medicines Ltd’s earnings last quarter?
BeOne Medicines Ltd released its earnings results on Feb 26, 2026. The company reported HK$0.361 earnings per share for the quarter, missing the consensus estimate of HK$0.746 by -HK$0.385.
Is BeOne Medicines Ltd overvalued?
According to Wall Street analysts BeOne Medicines Ltd’s price is currently Undervalued.
Does BeOne Medicines Ltd pay dividends?
BeOne Medicines Ltd does not currently pay dividends.
What is BeOne Medicines Ltd’s EPS estimate?
BeOne Medicines Ltd’s EPS estimate is 0.62.
How many shares outstanding does BeOne Medicines Ltd have?
BeOne Medicines Ltd has 1,540,976,000 shares outstanding.
What happened to BeOne Medicines Ltd’s price movement after its last earnings report?
BeOne Medicines Ltd reported an EPS of HK$0.361 in its last earnings report, missing expectations of HK$0.746. Following the earnings report the stock price went down -9.159%.
Which hedge fund is a major shareholder of BeOne Medicines Ltd?
Currently, no hedge funds are holding shares in HK:6160
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
BeOne Medicines Ltd Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
HK$244.26 (33.99% Upside)
HK$244.26 (33.99% Upside)
News Sentiment
Bullish
Bullish news 67%
Bearish news 33%
Bearish news 33%
Technicals
SMA
Positive
20 days / 200 days
Momentum
39.37%
12-Months-Change
Fundamentals
Return on Equity
7.28%
Trailing 12-Months
Asset Growth
39.22%
Trailing 12-Months
Company Description
BeOne Medicines Ltd
BeiGene Ltd. is a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.
6160 Stock 12 Month Forecast
Average Price Target
HK$244.26
▲(33.99% Upside)
Technical Analysis
Innovent Biologics
―
Wuxi Biologics (Cayman)
―
WuXi AppTec Co., Ltd. Class H
―
Hansoh Pharmaceutical Group Company Limited
―
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H
―
Options Prices
Currently, No data available
---